statistiche ricercatore

TOSI, GIOVANNA

Distribuzione geografica

Continente	#
NA - Nord America	11.373
EU - Europa	8.800
AS - Asia	5.280
SA - Sud America	496
AF - Africa	67
Continente sconosciuto - Info sul continente non disponibili	8
OC - Oceania	6
Totale	26.030

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	11.169
IT - Italia	4.329
SG - Singapore	1.669
UA - Ucraina	1.555
CN - Cina	1.198
VN - Vietnam	892
TR - Turchia	654
DE - Germania	589
SE - Svezia	577
HK - Hong Kong	564
FI - Finlandia	477
BR - Brasile	435
FR - Francia	315
IE - Irlanda	298
GB - Regno Unito	249
RU - Federazione Russa	243
CA - Canada	131
IN - India	100
MX - Messico	56
PL - Polonia	42
JP - Giappone	41
BE - Belgio	32
BD - Bangladesh	30
NL - Olanda	26
ZA - Sudafrica	26
ES - Italia	22
IQ - Iraq	20
AR - Argentina	19
PK - Pakistan	14
KR - Corea	12
LT - Lituania	11
MA - Marocco	11
AE - Emirati Arabi Uniti	10
EC - Ecuador	10
PH - Filippine	10
VE - Venezuela	9
EU - Europa	8
CH - Svizzera	7
IR - Iran	7
CZ - Repubblica Ceca	6
ID - Indonesia	6
KE - Kenya	6
MY - Malesia	6
NG - Nigeria	6
PE - Perù	6
PY - Paraguay	6
SA - Arabia Saudita	6
UZ - Uzbekistan	6
JO - Giordania	5
TN - Tunisia	5
TW - Taiwan	5
AT - Austria	4
CL - Cile	4
CO - Colombia	4
DZ - Algeria	4
JM - Giamaica	4
LB - Libano	4
AU - Australia	3
BY - Bielorussia	3
EG - Egitto	3
IL - Israele	3
KH - Cambogia	3
NP - Nepal	3
PA - Panama	3
RS - Serbia	3
BH - Bahrain	2
CI - Costa d'Avorio	2
DO - Repubblica Dominicana	2
GA - Gabon	2
GR - Grecia	2
HN - Honduras	2
HR - Croazia	2
MT - Malta	2
NZ - Nuova Zelanda	2
PR - Porto Rico	2
PS - Palestinian Territory	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AO - Angola	1
AZ - Azerbaigian	1
BB - Barbados	1
BG - Bulgaria	1
CR - Costa Rica	1
DK - Danimarca	1
GE - Georgia	1
GY - Guiana	1
KW - Kuwait	1
KZ - Kazakistan	1
MD - Moldavia	1
ME - Montenegro	1
MK - Macedonia	1
NO - Norvegia	1
OM - Oman	1
QA - Qatar	1
SY - Repubblica araba siriana	1
TG - Togo	1
TJ - Tagikistan	1
WS - Samoa	1
Totale	26.030

Salva come PNG Salva come JPEG

Città	#
Milan	3.337
Jacksonville	1.193
Fairfield	928
Singapore	927
San Jose	902
Ashburn	854
Chandler	783
Woodbridge	609
Hong Kong	556
Wilmington	429
Ann Arbor	424
Houston	410
Izmir	406
Princeton	398
Seattle	389
Dearborn	366
Beijing	363
Nyköping	297
Dublin	296
Dallas	289
Cambridge	287
Dong Ket	268
Boardman	236
The Dalles	235
Rome	233
Lauterbourg	173
San Mateo	138
New York	120
Los Angeles	103
Ho Chi Minh City	102
Como	91
Toronto	85
Helsinki	84
Council Bluffs	80
Hanoi	79
Chicago	77
San Diego	76
Ogden	69
Orem	67
Santa Clara	60
Guangzhou	59
Munich	53
São Paulo	53
Düsseldorf	45
Chennai	40
Tokyo	40
Warsaw	36
Hefei	35
Mexico City	33
Verona	33
Brussels	31
London	31
Manchester	29
Nanjing	28
Frankfurt am Main	26
Hangzhou	25
Norwalk	25
Shanghai	22
Turku	22
Boston	21
Kunming	21
Phoenix	21
Pune	20
Amsterdam	19
Brooklyn	19
Johannesburg	19
Denver	18
Jinan	18
Montreal	18
Falls Church	17
Stockholm	17
Da Nang	16
Fuzhou	16
Washington	16
Shenzhen	15
St Petersburg	15
Columbus	14
Haiphong	14
Poplar	14
San Francisco	14
Atlanta	11
Belo Horizonte	11
Mumbai	11
Zhengzhou	11
Nuremberg	10
Baghdad	9
Brasília	9
Changsha	9
Curitiba	9
Kocaeli	9
Ankara	8
Buffalo	8
Kilburn	8
Nanchang	8
Porto Alegre	8
Querétaro	8
Rio de Janeiro	8
Tianjin	8
Chongqing	7
Dhaka	7
Totale	18.024

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	265
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	244
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	236
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	217
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	215
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	212
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	208
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	208
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	207
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	205
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	204
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	202
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	200
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	196
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	196
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	193
The MHC class II transactivator: prey and hunter in infectious diseases	191
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	189
Autoimmunità e Malattie Autoimmuni	188
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	186
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	182
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	181
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis	177
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	176
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	176
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	176
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	175
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	174
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	172
A dual defensive role of CIITA against retroviral infections	169
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	169
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	169
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	167
New approaches of cancer vaccination and cancer immunotherapy based on the optimal stimulation of tumor-specific, MHC class II-restricted CD4+ T helper cells	164
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	163
Associazione tra genotipo HLA-DQ e suscettibilità al Diabete insulino-Dipendente	163
MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?	161
Time-Resolved Förster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA	161
CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity	158
Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers	157
Tax-1-mediated HTLV-1 replication and NF-kB activation is inhibited by the MHC-II transactivator CIITA	157
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	156
HLA-DQ genotype in early onset insulin dependent diabetes mellitus	156
Analysis of microchimerism in thyroid autoimmune diseases	156
The MHC-II transactivator CIITA inhibits Tat-mediated HIV-1 LTR transactivation and virus replication in human U937 monocytic cells	156
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	156
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	155
Tax-1-mediated NF-kB activation is inhibited by the MHC-II transactivator CIITA	155
Tat protein is an HIV-1 encoded SS-chemochine homolog that promotes migrationand upregulates CCR3 on human FceRI+ cells	154
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	154
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	154
MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to and affecting Tax-2 intracellular localization	154
Apparente dissociazione tra fenotipo DR e genotipo MHC di classe II in IDDM	153
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes	153
Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters	152
Molecular typing of polymorphic genes by time-resolved fluorescence resonance energy transfer	150
Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication.	150
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	149
The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein	147
Distinct subcellular localization of HTLV-1 HBZ oncoprotein in the ATL leukemic and HAM/TSP patients.	146
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	144
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1	143
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	143
The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-kappa B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein	143
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	142
Role of the HLA-DQ genotype in IDDM susceptibility	142
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	141
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	141
The MHC Class II transactivator, CIITA,is a viral restriction factor for human oncogenic retroviruses	140
HLA-DQB1 typing of north east italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-Enzyme Immunoassay (DEIA)	139
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines	138
The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for Insulin-Dependent Diabetes Mellitus	138
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	137
Expression of MHC class I and class II antigens in pancreatic adenocarcinomas	137
Associazione tra HLA-DQB1 e diabete giovanile analizzata a livello molecolare per Southern e DEIA	137
HTLV-2 Tax-2 transactivator increases the expression and the function of its inhibitor CIITA, the master regulator of HLA-II gene transcription	137
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	137
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	137
Cellular and molecular aspects of immune response relevant to autoimmune diseases	136
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	136
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	135
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	135
The constitutive activation of NF-kB by HTLV-1 Tax-1 oncoprotein is inhibited by the MHC class II transactivator CIITA	135
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	134
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	133
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic Virus Type 1	133
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	132
Host-retrovirus interaction: role of CIITA in the inhibition of HTLV-1 replication and oncogenic potential	132
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	130
Human T-cell leukemia virus type II directly acts on CD34+ hematopoietic precursors by increasing their survival potential. Envelope associated HLA class II molecules reverse this effect	128
Regulation of HLA antigen expression in HIV infected cells	128
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	127
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	125
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	125
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	125
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	123
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	123
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	123
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	123
Totale	16.059

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	97.415
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	97.415

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	876	0	0	0	0	0	0	0	0	0	102	242	532
2021/2022	1.700	211	223	152	133	42	48	57	123	83	222	159	247
2022/2023	2.159	252	86	120	258	159	493	0	292	312	63	69	55
2023/2024	4.884	816	801	919	824	877	310	50	40	155	20	9	63
2024/2025	2.562	10	45	483	50	107	108	123	141	313	158	220	804
2025/2026	5.556	492	363	187	862	539	448	1.407	371	620	267	0	0
Totale													26.096